Karyopharm Therapeutics
Latest round
- Series B
Last raised
- Jul 2013
Total raised
- $60M
Investors
- 4
About Karyopharm Therapeutics
Karyopharm Therapeutics specializes in creating advanced cancer treatments. Founded by Michael Kauffman and Sharon Shacham, the company is headquartered in Natick, US.8 million shares at USD 16 each.Karyopharm Therapeutics Inc. specializes in developing innovative cancer therapies, with a particular focus on oral Selective Inhibitor of Nuclear Export (SINE) technology. Their core product offerings primarily include novel treatments aimed at addressing various oncological conditions, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL). These therapies are designed to target critical mechanisms involved in cancer cell growth and survival, ultimately enhancing treatment efficacy for patients with high unmet medical needs.Karyopharm's revenue generation model is rooted in the commercialization of its proprietary cancer therapies.24 mn. Karyopharm engages in direct-to-consumer sales and B2B transactions with healthcare institutions, such as hospitals and specialized clinics.Karyopharm Therapeutics aims to expand its portfolio by launching new products designed to enhance cancer treatment options. The company is actively seeking to penetrate additional regions in North America and Europe by the end of 2025, enhancing its global reach and improving access to its therapies for patients.
Who invested in Karyopharm Therapeutics
4 investors across 3 rounds
See all investors in Karyopharm Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Karyopharm Therapeutics
Who invested in Karyopharm Therapeutics?
Karyopharm Therapeutics has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Karyopharm Therapeutics raised?
Karyopharm Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Karyopharm Therapeutics last raise money?
Karyopharm Therapeutics's most recent round on record is a Series B, in Jul 2013.
What does Karyopharm Therapeutics do?
Karyopharm Therapeutics specializes in creating advanced cancer treatments.
Where is Karyopharm Therapeutics headquartered?
Karyopharm Therapeutics is headquartered in Natick, US.
Which VCs invest in companies like Karyopharm Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Karyopharm Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Karyopharm Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.